: Amarin’s stock is up 17% on strong revenue estimates for 2022


U.S.-listed shares of Amarin Corp. PLC AMRN, +17.23% rallied about 17% in trading on Tuesday afternoon after the company shared better-than-expected sales estimates for 2022. In a news release and during a presentation at the J.P. Morgan Healthcare Conference, Amarin said it now expects revenue of $367 million to $369 million for the year. The FactSet consensus is $365 million. Amarin’s stock is down 48.3% over the past 12 months, while the S&P 500 SPX, +0.28% has declined 16.8%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleMarket Snapshot: U.S. stocks drift after Powell talk, with inflation data and earnings on horizon
Next articleHere are 18 stock picks if consumers find themselves in a ‘Goldilocks’ scenario


Please enter your comment!
Please enter your name here